[{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"AJU Pharm","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"ST-100","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Stuart Therapeutics \/ AJU Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Stuart Therapeutics \/ AJU Pharm"}]

Find Clinical Drug Pipeline Developments & Deals for ST-100

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ST-100 is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen.

                          Brand Name : ST-100

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          January 03, 2023

                          Lead Product(s) : ST-100

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : AJU Pharm

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank